Cape ANN Savings Bank Has $286,000 Stock Position in Amgen Inc. $AMGN

Cape ANN Savings Bank lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,023 shares of the medical research company’s stock after purchasing an additional 65 shares during the quarter. Cape ANN Savings Bank’s holdings in Amgen were worth $286,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Corundum Group Inc. grew its stake in Amgen by 80.6% during the second quarter. Corundum Group Inc. now owns 3,518 shares of the medical research company’s stock worth $982,000 after buying an additional 1,570 shares in the last quarter. Precedent Wealth Partners LLC boosted its position in shares of Amgen by 14.0% during the 2nd quarter. Precedent Wealth Partners LLC now owns 7,136 shares of the medical research company’s stock worth $1,992,000 after acquiring an additional 877 shares in the last quarter. Fairvoy Private Wealth LLC boosted its position in shares of Amgen by 1.1% during the 2nd quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock worth $885,000 after acquiring an additional 35 shares in the last quarter. DHJJ Financial Advisors Ltd. boosted its position in shares of Amgen by 44.8% during the 2nd quarter. DHJJ Financial Advisors Ltd. now owns 320 shares of the medical research company’s stock worth $89,000 after acquiring an additional 99 shares in the last quarter. Finally, Mattern Capital Management LLC boosted its position in shares of Amgen by 2.6% during the 2nd quarter. Mattern Capital Management LLC now owns 33,893 shares of the medical research company’s stock worth $9,463,000 after acquiring an additional 852 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Friday. Morgan Stanley raised their price objective on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c+)” rating on shares of Amgen in a research note on Saturday, September 27th. Piper Sandler raised their price target on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research note on Monday, August 25th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $305.00 target price on shares of Amgen in a research report on Tuesday, June 24th. Seven investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $309.70.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.76% of the stock is currently owned by corporate insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $297.89 on Friday. The firm has a market cap of $160.37 billion, a PE ratio of 24.36, a price-to-earnings-growth ratio of 2.58 and a beta of 0.49. The firm’s fifty day moving average is $287.34 and its 200-day moving average is $288.36. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $335.88.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were issued a dividend of $2.38 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.2%. Amgen’s payout ratio is presently 77.84%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.